Teva Phase 2a Celiac Disease Trial Success
Analysis based on 11 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026
Positive clinical data for TEV '408 could boost Teva's stock as it validates a key pipeline asset with potential in multiple indications. The results may also increase confidence in Teva's innovative drug strategy and its partnership with Royalty Pharma.
Sun Pharma announced positive topline results from its Phase 2a study of TEV '408, an investigational anti-IL-15 monoclonal antibody, in adults with celiac disease. The study met its primary endpoint, showing statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8. TEV '408 was well-tolerated with no safety signals observed. These results, combined with the vitiligo program, support TEV '408 as a potential pipeline-in-a-product opportunity. Teva plans to present further data at a future scientific meeting and will hold an investor call to discuss the results.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard